European Bladder Cancer Therapeutics MarketsFrost & SullivanAugust 14, 2007 94 Pages - SKU: MC1551132 |
| Countries covered: Europe This Frost & Sullivan research service titled European Bladder Cancer Therapeutics Markets presents a concise analysis of the market that includes challenges, factors driving growth and the revenue forecasts from 2003 to 2013. The study identifies the competitive opportunities within the market as well as strategies to exploit these opportunities and overcome industry challenges. In this research, Frost & Sullivan's expert analysts thoroughly examine the cytotoxic (chemotherapy therapies) and targeted therapies segments. This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Services programme. With this programme, clients receive industry-leading market research such as this, along with technical and econometric data and many interactive features including Analyst Inquiry Time and Client Councils. Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
The following technologies are covered in this research:
Incapacity of Existing Bladder Cancer Therapies to Improve Long-term Patient Survival Rates Create Need for Superior Treatment Methods Despite aggressive therapy with curative intent, muscle-invasive diseases continue to be responsible for patient mortality. The failure of several developments to improve the long-term survival rate of patients with bladder cancer is creating the need for new and advanced treatment methods. "As five-year survival rates in patients receiving conventional systemic therapy for metastatic disease are poor, there is a huge unmet need for novel treatments that improve survival or increase the therapeutic ratio of systemic therapy," explains the analyst of this research service. Moreover, no new drugs for bladder cancer have entered the market in two decades, which encourages the scope for novel treatments in the market. Emerging treatment options include new cytotoxic drugs, new targeted therapies and new biological treatments, which include gene therapy. If these treatment options can offer greater clinical efficacy compared to existing treatments, it will drive the market immensely. Novel forms of therapy are much needed for patients with metastatic disease in particular, since the current treatment is only chemotherapy and/or radiotherapy. Market Participants Must Explore New Areas of Drug Development and Delivery to Offset Impact of Mature Product Lines Since chemotherapy and immunotherapy treatments have been in the market for decades, they have become heavily dominated by generics and this in turn has limited growth potential. "Companies developing drugs such as cisplatin, doxorubicin and methotrexate need to explore new areas of development and different ways to grow," notes the analyst. "This can extend treatment opportunities, patient groups and could help deliver the drug more effectively." The strategic aim in the mature stage of the product life cycle is to win over customers from competitors and increase usage by offering value-added features such as the drug delivery mechanism. Research is being carried out to improve the outcomes of Mitomycin and Bacillus Calmette-Guerin (BCG) through different delivery mechanisms such as electromotive (intravesical electric current) drug delivery. |
More Europe Oncology/Hematology Reports
2012 European Tumor Marker Testing Market:France, Germany, Italy, Spain, UK Emerging Opportunities and Business Expansion Strategies by
Venture Planning Group
This unique report provides information not available from any other published source, including volume, sales, and leading supplier shares by test. This comprehensive five-country report identifies ...
2012 UK Tumor Marker Testing Market Outlook: Growth Opportunities and Strategies by
Venture Planning Group
Highlights Comprehensive 575-page analysis of the UK tumor marker testing market. Major issues pertaining to the UK laboratory practice, as well as key economic, regulatory, demographic, social ...
2012 Spain Tumor Marker Testing Market Outlook: Growth Opportunities and Strategies by
Venture Planning Group
Highlights Comprehensive 565-page analysis of the Spanish tumor marker testing market. Major issues pertaining to the Spanish laboratory practice, as well as key economic, regulatory, demographic, social ...
2012 Italy Tumor Marker Testing Market Outlook: Growth Opportunities and Strategies by
Venture Planning Group
Highlights Comprehensive 570-page analysis of the Italian tumor marker testing market. Major issues pertaining to the Italian laboratory practice, as well as key economic, regulatory, demographic, social ...
2012 Germany Tumor Marker Testing Market Outlook: Growth Opportunities and Strategies by
Venture Planning Group
Highlights Comprehensive 585-page analysis of the German tumor marker testing market. Major issues pertaining to the German laboratory practice, as well as key economic, regulatory, demographic, social ...
See all reports like this >>
More Europe Reports
A Comprehensive Study Of The UK Video Conferencing Equipment Market In 2010, Rating & Valuing Each Of The 30 Companies That Operate In Today's Market by
Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...
A Comprehensive Study Of The UK Tableware Market In 2010, Rating & Valuing Each Of The 166 Companies That Operate In Today's Market by
Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...
A Comprehensive Study Of The UK Surveyors & Valuers Market In 2010, Rating & Valuing Each Of The 943 Companies That Operate In Today's Market by
Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...
A Comprehensive Study Of The UK Subsea Engineering Market In 2010, Rating & Valuing Each Of The 142 Companies That Operate In Today's Market by
Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...
A Comprehensive Study Of The UK Structural Engineering Consultancy Market In 2010, Rating & Valuing Each Of The 300 Companies That Operate In Today's Market by
Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...
See all reports like this >>
Related Markets
Oncology/Hematology Reports
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Peptides
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Angiogenesis and Protein Kinase Inhibitors
